Gri Bio Etf Price Prediction
| GRI Etf | USD 1.99 0.02 1.02% |
Momentum 62
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (1.00) | EPS Estimate Current Year (4.04) | EPS Estimate Next Year (2.17) | Wall Street Target Price 22 | EPS Estimate Current Quarter (3.79) |
Using GRI Bio hype-based prediction, you can estimate the value of GRI Bio from the perspective of GRI Bio response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in GRI Bio to buy its etf at a price that has no basis in reality. In that case, they are not buying GRI because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell etfs at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
GRI Bio after-hype prediction price | USD 2.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as etf price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out GRI Bio Basic Forecasting Models to cross-verify your projections. GRI Bio After-Hype Price Prediction Density Analysis
As far as predicting the price of GRI Bio at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in GRI Bio or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Etf prices, such as prices of GRI Bio, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
GRI Bio Estimiated After-Hype Price Volatility
In the context of predicting GRI Bio's etf value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on GRI Bio's historical news coverage. GRI Bio's after-hype downside and upside margins for the prediction period are 0.10 and 7.63, respectively. We have considered GRI Bio's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
GRI Bio is risky at this time. Analysis and calculation of next after-hype price of GRI Bio is based on 3 months time horizon.
GRI Bio Etf Price Prediction Analysis
Have you ever been surprised when a price of a ETF such as GRI Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GRI Bio backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Etf price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with GRI Bio, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.33 | 5.63 | 0.01 | 0.03 | 8 Events / Month | 6 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.99 | 2.00 | 0.50 |
|
GRI Bio Hype Timeline
On the 26th of July GRI Bio is traded for 1.99. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.03. GRI is projected to increase in value after the next headline, with the price projected to jump to 2.0 or above. The average volatility of media hype impact on the company the price is over 100%. The price growth on the next news is projected to be 0.5%, whereas the daily expected return is currently at 0.33%. The volatility of related hype on GRI Bio is about 6929.23%, with the expected price after the next announcement by competition of 1.96. Reported Net Loss for the year was (8.21 M) with profit before taxes, overhead, and interest of 0. Considering the 90-day investment horizon the next projected press release will be in about 8 days. Check out GRI Bio Basic Forecasting Models to cross-verify your projections.GRI Bio Related Hype Analysis
Having access to credible news sources related to GRI Bio's direct competition is more important than ever and may enhance your ability to predict GRI Bio's future price movements. Getting to know how GRI Bio's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how GRI Bio may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| BDRX | Biodexa Pharmaceticals | (0.1) | 9 per month | 0.00 | (0.10) | 6.92 | (12.77) | 44.28 | |
| CLNN | Clene Inc | (0.08) | 10 per month | 4.31 | 0.04 | 10.55 | (5.03) | 73.61 | |
| FHTX | Foghorn Therapeutics | (0.1) | 9 per month | 3.11 | 0.12 | 9.11 | (5.56) | 20.82 | |
| HOWL | Werewolf Therapeutics | 0.04 | 10 per month | 4.10 | 0.11 | 12.12 | (6.92) | 35.53 | |
| IKNA | Ikena Oncology | 0.02 | 7 per month | 2.94 | 0.04 | 6.72 | (3.94) | 18.39 | |
| IMNM | Immunome | (0.41) | 9 per month | 3.47 | 0.10 | 6.82 | (6.18) | 15.79 | |
| TNON | Tenon Medical | (0.01) | 5 per month | 3.07 | (0.06) | 6.12 | (5.77) | 26.41 | |
| TVGN | Tevogen Bio Holdings | (0.01) | 11 per month | 4.94 | 0.02 | 8.06 | (5.17) | 32.25 |
GRI Bio Additional Predictive Modules
Most predictive techniques to examine GRI price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for GRI using various technical indicators. When you analyze GRI charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About GRI Bio Predictive Indicators
The successful prediction of GRI Bio stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as GRI Bio, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of GRI Bio based on analysis of GRI Bio hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to GRI Bio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to GRI Bio's related companies.
Story Coverage note for GRI Bio
The number of cover stories for GRI Bio depends on current market conditions and GRI Bio's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that GRI Bio is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about GRI Bio's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
GRI Bio Short Properties
GRI Bio's future price predictability will typically decrease when GRI Bio's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of GRI Bio often depends not only on the future outlook of the potential GRI Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. GRI Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 183.3 K | |
| Cash And Short Term Investments | 5 M |
Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.